## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($95.02)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel**
- Source: Business Wire | 20251202T010953 | Bullish | Relevance: 99%
-  Incyte (Nasdaq:INCY) has announced the appointment of Richard Hoffman as Executive Vice President and General Counsel, effective December 1, 2025. Mr. Hoffman brings over 20 years of experience in corporate governance and business development, having previously served as a Partner at Goodwin's Life Sciences group. He will be a key member of the Executive Leadership Team, overseeing the Company's legal and compliance functions.

**2. Incyte Corp. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170600 | Neutral | Relevance: 99%
-  Incyte Corp. (INCY) stock fell by 2.32% to $102.04 on Monday, significantly underperforming the broader market. This decline occurred during a tough trading session where the S&P 500 Index dropped 0.53% and the Dow Jones Industrial Average fell 0.90%. This marks the second consecutive day of losses for Incyte Corp.

**3. INCY: Late-stage pipeline and global expansion drive strong post-Jakafi growth outlook**
- Source: TradingView | 20251202T200615 | Bullish | Relevance: 99%
- Incyte Corporation outlined a post-Jakafi growth strategy focusing on its robust late-stage pipeline across hematology, oncology, and immunology, presenting multiple billion-dollar opportunities. Key assets like 989 for MPNs, the global expansion of Opzelura, povorcitinib for HS/PN/vitiligo, and solid tumor programs are expected to drive growth. This strategy is supported by strong execution and business development efforts.

**4. INCY: Late-stage pipeline and global expansion drive strong post-Jakafi growth outlook**
- Source: TradingView | 20251202T190613 | Bullish | Relevance: 99%
- Incyte Corporation's management has outlined a robust post-Jakafi growth strategy, focusing on a late-stage pipeline in hematology, oncology, and immunology with multiple billion-dollar opportunities. Key assets include 989 for MPNs, the global expansion of Opzelura, povorcitinib for HS and PN, and various solid tumor programs. This strategy is underpinned by strong execution and business development efforts.

**5. Incyte Corp. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170600 | Neutral | Relevance: 99%
-  Incyte Corp. (INCY) stock fell by 2.32% to $102.04 on Monday, marking its second consecutive day of losses. This underperformance occurred during a general market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.2 |
| Current P/E | 14.8 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 3.0% to -4.6% (-7.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Underperforming sector by 4.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-0.91), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.61% (CS: 15) | Weak |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 1.075x | Above |
| vs SMA200 | 1.333x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $101.44
- **Stop Loss:** $95.02 (6.3% risk)
- **Target:** $114.28 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 155
- **Position Value:** $15,723.20
- **Portfolio %:** 15.72%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*